CL2022001030A1 - Compuestos moduladores de glp-1r - Google Patents
Compuestos moduladores de glp-1rInfo
- Publication number
- CL2022001030A1 CL2022001030A1 CL2022001030A CL2022001030A CL2022001030A1 CL 2022001030 A1 CL2022001030 A1 CL 2022001030A1 CL 2022001030 A CL2022001030 A CL 2022001030A CL 2022001030 A CL2022001030 A CL 2022001030A CL 2022001030 A1 CL2022001030 A1 CL 2022001030A1
- Authority
- CL
- Chile
- Prior art keywords
- glp
- modulating compounds
- compounds
- agonists
- kits
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente divulgación proporciona agonistas de GLP-1R y composiciones, métodos y kits de los mismos. Dichos compuestos son generalmente útiles para tratar una enfermedad o afección mediada por GLP-1R en un ser humano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962926270P | 2019-10-25 | 2019-10-25 | |
US202063028187P | 2020-05-21 | 2020-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022001030A1 true CL2022001030A1 (es) | 2023-02-03 |
Family
ID=73449207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022001030A CL2022001030A1 (es) | 2019-10-25 | 2022-04-22 | Compuestos moduladores de glp-1r |
Country Status (16)
Country | Link |
---|---|
US (2) | US11702404B2 (es) |
EP (1) | EP4048664A1 (es) |
JP (2) | JP7558267B2 (es) |
KR (1) | KR20220092909A (es) |
CN (1) | CN114630823A (es) |
AU (2) | AU2020369568B2 (es) |
BR (1) | BR112022007627A2 (es) |
CA (1) | CA3157525A1 (es) |
CL (1) | CL2022001030A1 (es) |
CO (1) | CO2022005077A2 (es) |
CR (1) | CR20220178A (es) |
IL (1) | IL292399A (es) |
MX (1) | MX2022004874A (es) |
PE (1) | PE20221040A1 (es) |
TW (1) | TWI790492B (es) |
WO (1) | WO2021081207A1 (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4364798A3 (en) | 2018-10-05 | 2024-06-19 | Annapurna Bio Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
CA3136375A1 (en) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
KR20220092909A (ko) | 2019-10-25 | 2022-07-04 | 길리애드 사이언시즈, 인코포레이티드 | Glp-1r 조절 화합물 |
US20230002348A1 (en) * | 2019-11-15 | 2023-01-05 | Ildong Pharmaceutical Co., Ltd. | GLP-1 Receptor Agonist and Use Thereof |
KR20210059584A (ko) * | 2019-11-15 | 2021-05-25 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
WO2021112538A1 (en) | 2019-12-02 | 2021-06-10 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
EP4097097A1 (en) | 2020-01-29 | 2022-12-07 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
EP4097099B1 (en) | 2020-02-07 | 2024-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
TWI825398B (zh) * | 2020-03-18 | 2023-12-11 | 南韓商Lg化學股份有限公司 | Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法 |
KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
AR123156A1 (es) * | 2020-08-06 | 2022-11-02 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r y sus usos |
CA3190163A1 (en) | 2020-08-06 | 2022-02-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
CN116406360A (zh) | 2020-08-28 | 2023-07-07 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
MX2023003995A (es) | 2020-10-05 | 2023-06-12 | Enliven Inc | Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl. |
EP4227299A1 (en) * | 2020-10-12 | 2023-08-16 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Benzimidazolone glp-1 receptor agonist and use thereof |
CN116547279A (zh) * | 2020-10-13 | 2023-08-04 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
WO2022111624A1 (zh) * | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
CN114591308B (zh) * | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するglp-1受容体作動薬を含有する医薬組成物 |
EP4303215A4 (en) * | 2021-04-08 | 2024-09-18 | Lg Chemical Ltd | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING IT AND PREPARATION METHOD THEREOF |
WO2022225914A1 (en) * | 2021-04-21 | 2022-10-27 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
PE20240362A1 (es) * | 2021-04-21 | 2024-03-04 | Gilead Sciences Inc | Compuestos moduladores del glp-ir carboxibenzimidazolicos |
TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
CN117098758A (zh) | 2021-06-24 | 2023-11-21 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
CA3227366A1 (en) * | 2021-08-04 | 2023-02-09 | Yidong Su | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
JP2024532518A (ja) * | 2021-08-30 | 2024-09-05 | 杭州徳睿智薬科技有限公司 | Glp1rアゴニストとしての新規アリールエーテル置換複素環式化合物 |
JPWO2023038039A1 (es) | 2021-09-08 | 2023-03-16 | ||
MX2024003872A (es) * | 2021-09-27 | 2024-04-19 | Terns Pharmaceuticals Inc | Acidos carboxilicos de benzimidazol como agonistas de glp-1r. |
WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
EP4412707A1 (en) | 2021-10-05 | 2024-08-14 | Astrazeneca AB | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023138684A1 (en) * | 2022-01-24 | 2023-07-27 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
IL315275A (en) * | 2022-02-28 | 2024-10-01 | Ascletis Bioscience Co Ltd | GLP-1R modulatory compounds |
WO2023169436A1 (zh) | 2022-03-08 | 2023-09-14 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
WO2023222084A1 (zh) * | 2022-05-20 | 2023-11-23 | 成都地奥九泓制药厂 | 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用 |
WO2024028795A1 (en) * | 2022-08-04 | 2024-02-08 | Zydus Lifesciences Limited | Heterobicyclic compounds as oral glp1r agonists |
WO2024041609A1 (zh) * | 2022-08-24 | 2024-02-29 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
WO2024046342A1 (zh) * | 2022-08-30 | 2024-03-07 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
WO2024051749A1 (zh) * | 2022-09-06 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途 |
WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
TW202432122A (zh) * | 2022-12-13 | 2024-08-16 | 中國大陸商杭州中美華東製藥有限公司 | Glp-1受體激動劑的新晶型和製備方法及其藥物組合物和用途 |
CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
US20240360122A1 (en) * | 2023-03-29 | 2024-10-31 | Terns (Suzhou) Biotechnology Co., Ltd. | Polymorphic forms and salts of a glp-1r agonist |
WO2024206878A1 (en) * | 2023-03-29 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂,其制备方法和应用 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2339018A1 (en) | 1998-08-07 | 2000-02-17 | Applied Research Systems Ars Holding N.V. | Fsh mimetics for the treatment of infertility |
EP1429759A4 (en) | 2001-09-26 | 2004-12-15 | Bristol Myers Squibb Co | COMPOUNDS FOR TREATING HEPATITIS C VIRUS |
MXPA05011539A (es) | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. |
WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
CA2588766A1 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids |
EP1838690A2 (en) | 2004-12-21 | 2007-10-03 | Devgen N.V. | Compounds with kv4 ion channel activity |
NZ566276A (en) | 2005-09-16 | 2011-03-31 | Arrow Therapeutics Ltd | Biphenyl derivatives and their use in treating hepatitis C |
BRPI0711040A2 (pt) | 2006-03-31 | 2011-08-23 | Astrazeneca Ab | uso de um composto, método para o tratamento ou prevenção de distúrbios, composto, e, composição farmacêutica |
WO2008033455A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
CA2736970A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Pyrimidinone derivatives for use as medicaments |
US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
CN103153995B (zh) * | 2010-06-24 | 2016-08-10 | 武田药品工业株式会社 | 作为磷酸二酯酶(pdes)抑制剂的稠合杂环化合物 |
BR112014003499A2 (pt) | 2011-08-15 | 2017-06-13 | Intermune Inc | compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula |
CN103059014B (zh) * | 2011-10-21 | 2016-05-18 | 北京韩美药品有限公司 | 新型杂芳基氨基衍生物 |
CN104428293B (zh) | 2012-06-11 | 2018-06-08 | Ucb生物制药私人有限公司 | 调节TNFα的苯并咪唑类 |
WO2016018701A1 (en) * | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
KR20160066490A (ko) | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
MX2017009408A (es) | 2015-01-20 | 2017-10-02 | Merial Inc | Compuestos antihelminticos, composiciones y metodo para usar los mismos. |
US20170035881A1 (en) * | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
CA3015201C (en) * | 2016-03-30 | 2023-07-04 | Ishihara Sangyo Kaisha, Ltd. | Pyridazinone compound or its salt, and herbicide containing it |
BR112019012211A2 (pt) * | 2016-12-16 | 2019-11-12 | Pfizer | agonistas de receptor de glp-1 e usos dos mesmos |
CA3058182A1 (en) | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
US20200308165A1 (en) | 2017-09-13 | 2020-10-01 | D.E. Shaw Research, Llc | Compounds as Ras Inhibitors and Use Thereof |
MX2020008387A (es) | 2018-05-08 | 2020-12-11 | Vtv Therapeutics Llc | Usos terapeuticos de agonistas glp1r. |
TWI707683B (zh) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1受體促效劑及其用途 |
SG11202011704XA (en) | 2018-06-15 | 2020-12-30 | Pfizer | Glp-1 receptor agonists and uses thereof |
US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
AU2019382642A1 (en) * | 2018-11-22 | 2021-06-10 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
CA3136375A1 (en) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
CN112294760A (zh) | 2019-07-26 | 2021-02-02 | 张晋宇 | 一种液体制剂及其应用 |
WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
KR20220092909A (ko) | 2019-10-25 | 2022-07-04 | 길리애드 사이언시즈, 인코포레이티드 | Glp-1r 조절 화합물 |
KR20210053680A (ko) | 2019-11-04 | 2021-05-12 | 주식회사 엘지화학 | 광변조 디바이스의 제조 방법 |
US20230002348A1 (en) | 2019-11-15 | 2023-01-05 | Ildong Pharmaceutical Co., Ltd. | GLP-1 Receptor Agonist and Use Thereof |
WO2021112538A1 (en) | 2019-12-02 | 2021-06-10 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
EP4097097A1 (en) | 2020-01-29 | 2022-12-07 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
EP4097099B1 (en) | 2020-02-07 | 2024-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
US20230165846A1 (en) | 2020-02-13 | 2023-06-01 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
TWI825398B (zh) | 2020-03-18 | 2023-12-11 | 南韓商Lg化學股份有限公司 | Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法 |
JP2021155415A (ja) | 2020-03-27 | 2021-10-07 | ファイザー・インク | 2−[(4−{6−[(4−シアノ−2−フルオロベンジル)オキシ]ピリジン−2−イル}ピペリジン−1−イル)メチル]−1−[(2s)−オキセタン−2−イルメチル]−1h−ベンゾイミダゾール−6−カルボン酸またはその薬学的な塩を用いた2型糖尿病、または肥満、または過体重の治療 |
CN113493447B (zh) | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
CN115867546B (zh) | 2020-05-27 | 2024-10-18 | 上海齐鲁锐格医药研发有限公司 | Glp-1r激动剂的盐和晶形及其用途 |
AU2021286086B2 (en) | 2020-06-04 | 2023-09-07 | Hangzhou Sciwind Biosciences Co., Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
CN113816948B (zh) | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
AR123156A1 (es) * | 2020-08-06 | 2022-11-02 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r y sus usos |
IL300795A (en) | 2020-08-21 | 2023-04-01 | Terns Pharmaceuticals Inc | Compounds as GLP-1R agonists |
CN115515956B (zh) | 2020-09-29 | 2024-06-25 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
EP4227299A1 (en) | 2020-10-12 | 2023-08-16 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Benzimidazolone glp-1 receptor agonist and use thereof |
EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
WO2022111624A1 (zh) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
JP2024514259A (ja) * | 2021-04-08 | 2024-03-29 | エルジー・ケム・リミテッド | Glp-1受容体作動薬、それを含む薬学的組成物、およびその製造方法 |
CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
-
2020
- 2020-10-22 KR KR1020227017483A patent/KR20220092909A/ko not_active Application Discontinuation
- 2020-10-22 PE PE2022000662A patent/PE20221040A1/es unknown
- 2020-10-22 WO PCT/US2020/056867 patent/WO2021081207A1/en active Application Filing
- 2020-10-22 US US17/077,729 patent/US11702404B2/en active Active
- 2020-10-22 JP JP2022523351A patent/JP7558267B2/ja active Active
- 2020-10-22 CA CA3157525A patent/CA3157525A1/en active Pending
- 2020-10-22 AU AU2020369568A patent/AU2020369568B2/en active Active
- 2020-10-22 MX MX2022004874A patent/MX2022004874A/es unknown
- 2020-10-22 EP EP20807591.1A patent/EP4048664A1/en active Pending
- 2020-10-22 BR BR112022007627A patent/BR112022007627A2/pt unknown
- 2020-10-22 CR CR20220178A patent/CR20220178A/es unknown
- 2020-10-22 CN CN202080074611.4A patent/CN114630823A/zh active Pending
- 2020-10-23 TW TW109136833A patent/TWI790492B/zh active
-
2022
- 2022-04-20 IL IL292399A patent/IL292399A/en unknown
- 2022-04-22 CL CL2022001030A patent/CL2022001030A1/es unknown
- 2022-04-22 CO CONC2022/0005077A patent/CO2022005077A2/es unknown
-
2023
- 2023-05-10 US US18/195,767 patent/US20230391747A1/en active Pending
- 2023-11-10 JP JP2023192432A patent/JP2023184759A/ja active Pending
-
2024
- 2024-06-06 AU AU2024203850A patent/AU2024203850A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114630823A (zh) | 2022-06-14 |
CO2022005077A2 (es) | 2022-05-10 |
MX2022004874A (es) | 2022-05-13 |
BR112022007627A2 (pt) | 2022-07-12 |
EP4048664A1 (en) | 2022-08-31 |
AU2024203850A1 (en) | 2024-06-27 |
US11702404B2 (en) | 2023-07-18 |
KR20220092909A (ko) | 2022-07-04 |
AU2020369568B2 (en) | 2024-03-21 |
CA3157525A1 (en) | 2021-04-29 |
TW202130630A (zh) | 2021-08-16 |
WO2021081207A1 (en) | 2021-04-29 |
US20230391747A1 (en) | 2023-12-07 |
CR20220178A (es) | 2022-06-15 |
PE20221040A1 (es) | 2022-06-17 |
AU2020369568A1 (en) | 2022-05-05 |
TW202317535A (zh) | 2023-05-01 |
JP7558267B2 (ja) | 2024-09-30 |
JP2023184759A (ja) | 2023-12-28 |
TWI790492B (zh) | 2023-01-21 |
US20210171499A1 (en) | 2021-06-10 |
JP2022552735A (ja) | 2022-12-19 |
IL292399A (en) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001030A1 (es) | Compuestos moduladores de glp-1r | |
CO2023013766A2 (es) | Compuestos carboxi-benzimidazol moduladores de glp-1r | |
CL2023003119A1 (es) | Compuestos moduladores del glp-ir carboxibenzimidazólicos | |
CO2021005884A2 (es) | Moduladores de la alfa-1 antitripsina | |
CO2019007829A2 (es) | (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas | |
ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
ECSP21053104A (es) | Moduladores de la expresión de hsd17b13 | |
ECSP19072372A (es) | Moduladores de la expresión de pcsk9 | |
ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
EA201891664A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
CL2021001246A1 (es) | Moduladores de expresión irf5. | |
UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
PE20200749A1 (es) | Moduladores de la expresion de enac | |
EA202190045A1 (ru) | Составы/композиции, содержащие ибрутиниб | |
AR117079A1 (es) | Moduladores de la expresión de foxp3 | |
EA202191657A1 (ru) | Модуляторы экспрессии hsd17b13 | |
AR117593A1 (es) | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |